The operator of WeKnowDiets.com and other Web sites should clarify that it markets weight-loss supplement MiracleBurn - featured as the "most popular" product and a "customer choice award" winner on the site - according to the Electronic Retailing Self-Regulation Program. Urban Nutrition presented WeKnowDiets.com as a review forum for diet products, though a challenger argued to ERSP that the site "is premised on a deliberate intent to mislead consumers" by disguising ads as independent product reviews. The CBBB program recommended Aug. 11 that the firm disclose its material connection to the products it endorses. New York-based Urban Nutrition said it will "follow the ERSP's recommendations to reinforce several aspects of effective disclosure methods.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
The European Medicines Agency has OKd 10 new medicines for EU-wide approval, including a CAR-T therapy for treating acute lymphoblastic leukemia. Two drugs were, however, rejected.
